

FY24 FDA BAA Awards

Contract Number	Amount Obligated	Total Estimated Contract Value	Center	Awardee Name	Awardee Address	BAA Number	Award Title
75F40124C00013	\$1,956,704.00	\$1,956,704.00	CDER	Emerald Innovations Inc	1 BROADWAY CAMBRIDGE MA 02142	FY23C1FWP11	Development An Objective and Quantitative Endpoint for Atopic Dermatitis in Pediatric and Adult Populations
75F40124C00027	\$2,000,000.00	\$6,914,101.00	CDRH	Beth Israel Deaconess Medical Center	330 BROOKLINE AVENUE, 20 OV-5 BOSTON MA 02215	FY23C1JWP13	Large Scale Interactive Lab-Test Driven Insight Discovery Engine
75F40124C00094	\$1,014,000.00	\$2,161,743.00	CDER	CUBRC, Inc.	4455 GENESEE ST STE 106 BUFFALO NY 14225	FY24C2GP1	Developing Universal Control Peptides for T cell Assays Supporting Immunogenicity Assessments for Regulatory Filings
75F40124C00087	\$243,473.00	\$243,473.00	CDER	Columbia University	630 W 168TH ST FL 4 NEW YORK NY 10032	FY24C3DP2	Systematic Reviews of Vulnerable Pediatric Populations at Risks for Adverse Neurodevelopmental Outcome from Exposure to Opioid Analgesics, Anesthetic and Sedative Agents
75F40124C00131	\$569,780.00	\$2,235,290.00	CDER	University of Michigan	3003 S. STATE ST. ANN ARBOR MI 481091274	FY24C3DP3	A Mosaic Approach for Understanding Stimulant and Opioid Use and Use Disorder Trajectories and Associated Consequences in US Adults
75F40124C00106	\$951,000.00	\$3,376,000.00	CDER	Critical Path Institute	1840 E RIVER RD SUITE 100 TUCSON AZ 85718	FY24C1DP4	Development of drug development tools for ADTKD
75F40124C00118	\$399,999.00	\$399,999.00	CDER	The National Center for Natural Products Research, The University of Mississippi	113 Falkner UNIVERSITY MS 386779704	FY24C1CP18	Quality and Safety of Botanical Drug Candidates – Development of Chemical and Xenobiotic Profiles to Ensure the Clinical Relevancy of Herb-Drug Interaction Potentials
75F40124C00125	\$564,246.00	\$564,246.00	OCE	Purdue University	2550 NORTHWESTERN AVE # 1100 WEST LAFAYETTE IN 47906	FY24C1BP30	Advancing bispecific engagers for NK immunotherapy in pediatric gliomas
75F40124C00080	\$248,553.46	\$248,553.46	CDER	Institute for Clinical Pharmacodynamics	242 BROADWAY STE 101 SCHENECTADY NY 12305	FY24C3BP4	DEVELOPMENT OF MODERNIZED SUSCEPTIBILITY GUIDANCE FOR NITROFURANTOIN DOSING USING A DYNAMIC URINARY TRACT IN VITRO INFECTION MODEL AND PHARMACOMETRIC APPROACHES
75F40124C00128	\$978,324.00	\$978,324.00	CDER	The General Hospital Corporation d/b/a Massachusetts	55 FRUIT ST BOSTON MA 02114	FY24C3DP4	Enhance FDA's SOURCE model by incorporating and analyzing state and regional-level data
75F40124C00081	\$1,050,310.00	\$1,050,310.00	CDER	Columbia University	630 WEST 168TH STREET BOX 49 NEW YORK NY 10032	FY24C3DP5	Neurodevelopmental and Mental Health Outcomes in Preterm Infants: Effects of Exposures to Opioid Analgesic, Anesthetic and Sedative Agents
75F40124C00119	\$2,982,375.00	\$2,982,375.00	CDER	Verantos, Inc	325 SHARON PARK DR #730 MENLO PARK CA 94025	FY24C1JP9	Valid Evidence and Reliable real-world data Increasing Fidelity and Yielding clarity in regulatory decision-making (VERIFY)
75F40124C00047	\$1,189,903.56	\$1,189,903.56	CDRH	HKS, Inc.	350 N SAINT PAUL ST STE 100 DALLAS TX 75201	FY24C1HP5	Developing a prototype virtual reality experience of home environments that foster health and wellness for those living with diabetes: A step towards health equity
75F40124C00083	\$699,087.00	\$699,087.00	CDRH	Duke University	2200 West Main Street, Suite 900 DURHAM NC 277088990	FY24C1IP2	Harnessing the Power of Benefit-Transfer Methods for Informed Regulatory Decision-Making: A Case Study on Diabetes Medical Devices
75F40124C00114	\$811,126.00	\$811,126.00	CDRH	Digital Medicine Society (DIME)	90 CANAL ST FL 4 BOSTON MA 02114	FY24C1DP11	A how-to-guide for technology developers and the life sciences to drive adoption of sDHTs in clinical trials
75F40124C00132	\$260,000.00	\$460,000.00	CDER	University of Maryland, Baltimore	220 ARCH STREET, OFFICE LEVEL 2 BALTIMORE MD 212011531	FY24C1CP43	Characterizing Albumin-bound Nanoparticle Drugs using wNMR
75F40124C00130	\$1,832,572.00	\$6,038,686.00	CBER	Stacy Springs and the Massachusetts Institute of Technology	77 MASSACHUSETTS AVE CAMBRIDGE MA 02139	FY24C1BP64	Advanced manufacturing approaches to improve rAAV gene therapy product quality and scalability
75F40124C00049	\$1,910,049.00	\$1,910,049.00	CDER	Accenture Federal Services, LLC. (Accenture)	800 N GLEBE RD STE 300 ARLINGTON VA 22203	FY24C3FP5	Multi-Regulatory Collaborative Framework in the Cloud
75F40124C00121	\$1,051,402.26	\$1,051,402.26	OC	DNAnexus	1975 W EL CAMINO REAL STE 204 MOUNTAIN VIEW CA 940402218	FY24C1KP5	PRISM High-Impact Platform Pilot for Pre-Submission Validation of eCTDs Supporting Sponsor-Reviewer Interaction
75F40124C00134	\$497,579.00	\$1,299,218.00	CDRH	PPD. The project will be delivered by members of the Patient-Centered Research team at Evidera, a PPD business	929 North Front Street WILMINGTON NC 28401	FY24C3CP5	Understanding heterogeneity in preferences for clinical trial participation in diverse patient populations
75F40124C00117	\$724,461.00	\$724,461.00	CDRH	PPD Development, part of ThermoFisher	929 N FRONT ST WILMINGTON NC 28401	FY24C1EP6	Cardiovascular-Kidney-Metabolic (CKM) Syndrome Patient-Reported Outcome (PRO) Burden Measure Assessment of the need to develop a novel, or modify an existing, measure and qualitative patient interviews
75F40124C00120	\$332,866.00	\$332,866.00	CDRH	Milken Institute	1250 4TH ST FL 2 SANTA MONICA CA 90401	FY24C1IP3	Defining the Value and Return on Investment of Patient Engagement in Medtech Product Development
75F40124C00129	\$762,969.00	\$762,969.00	CDER	American College of Emergency Physicians	4950 W ROYAL LN IRVING TX 75063	FY24C2AP12	Comprehensive Real-World Evidence on Off-Label Ketamine Safety to Inform Regulatory and Clinical Decision Making
75F40124C00124	\$1,566,897.00	\$1,566,897.00	OCET	Advanced Regenerative Manufacturing Institute (ARMI)	400 COMMERCIAL ST MANCHESTER NH 03101	FY24C1BP70	A Scalable, Modular, Automated and Closed Medical Product Manufacturing System
	\$24,597,676.28	\$39,957,783.28					